PubMed · 11137963
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2001. SAMe for depression.. https://pubmed.ncbi.nlm.nih.gov/11137963/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
This study was designed to investigate the efficacy of the antidepressant fluvoxamine in the treatment of combat-related post-traumatic stress disorder (PTSD). Fifteen veterans with combat-related PTSD and no other psychiatric diagnosis except depression were recruited to participate in a 14-week open-label study of fluvoxamine. Patients underwent a 30-day washout period and were rated with the Clinician Administered PTSD Scale (CAPS), Mississippi Scale, Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) at baseline, and every 2 weeks until week 14. Three patients stopped fluvoxamine prematurely due to side effects and 7 withdrew consent before completing the 14-week trial. Eight patients completed at least 8 weeks of treatment. The total daily dose of fluvoxamine ranged from 100 to 300 mg with a mean daily dose of 150 mg at week 14. Intent-to-treat analysis revealed a significant improvement in total CAPS scores, and in the intrusion and the avoidance/numbing subscales. The CAPS hyper-arousal scores did not change significantly. HAM-A score also improved significantly. No significant changes were seen on the Mississippi scale, HAM-D, or Beck Depression Inventory in the intent-to-treat analysis. In summary, our study shows that fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted.
The purpose of this study is to examine relationships among self-care self-efficacy, depression, and quality of life in 160 patients receiving hemodialysis. The study is a descriptive, correlational design. Measures include Strategies Used by People to Promote Health, the Geriatric Depression Scale, and the Quality of Life Index. Results indicate that self-care self-efficacy and depression are the significant predictors of quality of life after controlling for the effect of age. Self-care self-efficacy explains 47.5% of the variance (beta=0.52, p<0.001) and depression (beta=-0.29, p<0.001) explains an additional 5.5% of variance in quality of life. The study provides important information for health care providers as they design interventions for patients receiving hemodialysis.